WellTheory has raised $14 million in Series A funding to advance AI-powered care for autoimmune diseases, targeting improvements for employers, payors, and patients across the rapidly growing market.
October 14, 2025
Source:
Unsplash / National Cancer Institute
Series A Investment Details
WellTheory, a virtual care platform focused on autoimmune diseases, has secured $14 million in Series A funding led by General Catalyst. Key participants include 7wire Ventures, Ingeborg Investments, Accel, Box Group, Leaps by Bayer, and Up2 Opportunity Fund. This brings WellTheory's total capital raised to $26.2 million.
Market Opportunity
Autoimmune diseases affect over 50 million Americans.
The autoimmune market is valued at $160 billion.
Rising drug costs are increasing the burden on employers and payors (Fierce Healthcare, MobiHealthNews).
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Pexels / Anna Shvets
Platform and Innovation
Whole-Person Care Approach
WellTheory integrates diet, lifestyle support, and medical treatment to manage autoimmune disease.
The company aims to improve patient experience and reduce costs for partners including employers and payors.
AI and Personalization
AI-enabled personalization is central, allowing for detailed risk assessments and tailored care plans. This differentiates WellTheory from traditional care models (Future Fem Health).
Read More
Source:
Unsplash / CDC
Share this news:
